{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T23:17:08Z","timestamp":1789859828734,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,10]],"date-time":"2016-10-10T00:00:00Z","timestamp":1476057600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2821-0","type":"journal-article","created":{"date-parts":[[2016,10,10]],"date-time":"2016-10-10T12:09:05Z","timestamp":1476101345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review"],"prefix":"10.1186","volume":"16","author":[{"given":"Mi\u0161o","family":"Gostimir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Moyana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harman","family":"Sekhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,10]]},"reference":[{"key":"2821_CR1","first-page":"e2476","volume":"344","author":"G Bond-Smith","year":"2012","unstructured":"Bond-Smith G, Banga N, Hammond TM, Imber CJ. Pancreatic adenocarcinoma. BMJ (Clinical research ed). 2012;344:e2476.","journal-title":"BMJ (Clinical research ed)"},{"key":"2821_CR2","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605\u201317.","journal-title":"N Engl J Med"},{"key":"2821_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","volume":"148","author":"AD Rhim","year":"2012","unstructured":"Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, et al. Emt and dissemination precede pancreatic tumor formation. Cell. 2012;148:349\u201361.","journal-title":"Cell"},{"key":"2821_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.cell.2011.11.060","volume":"148","author":"H Haeno","year":"2012","unstructured":"Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148:362\u201375.","journal-title":"Cell"},{"key":"2821_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000348527","volume":"36","author":"I Hartlapp","year":"2013","unstructured":"Hartlapp I, Muller J, Kenn W, Steger U, Isbert C, Scheurlen M, Germer CT, Einsele H, Kunzmann V. Complete pathological remission of locally advanced, unresectable pancreatic cancer (lapc) after intensified neoadjuvant chemotherapy. Onkologie. 2013;36:123\u20135.","journal-title":"Onkologie"},{"key":"2821_CR6","doi-asserted-by":"publisher","first-page":"e499","DOI":"10.1097\/MD.0000000000000499","volume":"94","author":"A Elias","year":"2015","unstructured":"Elias A, Chatzizacharias NA, Xanthis A, Corrie P, Davies S, Brais RJ, Jamieson NV, Praseedom RK, Huguet E, Harper SJ, et al. Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report. Medicine. 2015;94:e499.","journal-title":"Medicine"},{"issue":"Suppl 5","key":"2821_CR7","doi-asserted-by":"publisher","first-page":"v55","DOI":"10.1093\/annonc\/mdq165","volume":"21","author":"S Cascinu","year":"2010","unstructured":"Cascinu S, Falconi M, Valentini V, Jelic S. Pancreatic cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v55\u20138.","journal-title":"Ann Oncol"},{"key":"2821_CR8","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1245\/ASO.2006.08.011","volume":"13","author":"GR Varadhachary","year":"2006","unstructured":"Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035\u201346.","journal-title":"Ann Surg Oncol"},{"key":"2821_CR9","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.6004\/jnccn.2014.0106","volume":"12","author":"MA Tempero","year":"2014","unstructured":"Tempero MA, Malafa MP, Behrman SW, 3rd Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, et al. Pancreatic adenocarcinoma, version 2.2014: Featured updates to the nccn guidelines. J Natl Compr Canc Netw. 2014;12:1083\u201393.","journal-title":"J Natl Compr Canc Netw"},{"key":"2821_CR10","doi-asserted-by":"publisher","first-page":"10740","DOI":"10.3748\/wjg.v20.i31.10740","volume":"20","author":"NE Lopez","year":"2014","unstructured":"Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol. 2014;20:10740\u201351.","journal-title":"World J Gastroenterol"},{"key":"2821_CR11","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1245\/s10434-009-0408-6","volume":"16","author":"MP Callery","year":"2009","unstructured":"Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727\u201333.","journal-title":"Ann Surg Oncol"},{"key":"2821_CR12","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/annonc\/mdt141","volume":"24","author":"S Lorenzen","year":"2013","unstructured":"Lorenzen S, Thuss-Patience P, Al-Batran SE, Lordick F, Haller B, Schuster T, Pauligk C, Luley K, Bichev D, Schumacher G, et al. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol. 2013;24:2068\u201373.","journal-title":"Ann Oncol"},{"key":"2821_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.anndiagpath.2011.08.005","volume":"16","author":"Q Zhao","year":"2012","unstructured":"Zhao Q, Rashid A, Gong Y, Katz MH, Lee JE, Wolf R, Balachandran A, Varadhachary GR, Pisters PW, Wang H, et al. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012;16:29\u201337.","journal-title":"Ann Diagn Pathol"},{"key":"2821_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jso.23392","volume":"108","author":"BA Boone","year":"2013","unstructured":"Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, Stoller RG, Zeh HJ, Bahary N. Outcomes with folfirinox for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013;108:236\u201341.","journal-title":"J Surg Oncol"},{"key":"2821_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","volume":"261","author":"CR Ferrone","year":"2015","unstructured":"Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, et al. Radiological and surgical implications of neoadjuvant treatment with folfirinox for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261:12\u20137.","journal-title":"Ann Surg"},{"key":"2821_CR16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","volume":"54","author":"EA Mellon","year":"2015","unstructured":"Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta oncologica (Stockholm, Sweden). 2015;54:979\u201385.","journal-title":"Acta oncologica (Stockholm, Sweden)"},{"key":"2821_CR17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.clcc.2014.09.005","volume":"13","author":"SY Moorcraft","year":"2014","unstructured":"Moorcraft SY, Khan K, Peckitt C, Watkins D, Rao S, Cunningham D, Chau I. Folfirinox for locally advanced or metastatic pancreatic ductal adenocarcinoma: the royal marsden experience. Clin Colorectal Cancer. 2014;13:232\u20138.","journal-title":"Clin Colorectal Cancer"},{"issue":"Suppl 3","key":"2821_CR18","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1245\/s10434-015-4851-2","volume":"22","author":"U Nitsche","year":"2015","unstructured":"Nitsche U, Wenzel P, Siveke JT, Braren R, Holzapfel K, Schlitter AM, Stoss C, Kong B, Esposito I, Erkan M, et al. Resectability after first-line folfirinox in initially unresectable locally advanced pancreatic cancer: a single-center experience. Ann Surg Oncol. 2015;22 Suppl 3:1212\u201320.","journal-title":"Ann Surg Oncol"},{"key":"2821_CR19","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1097\/MD.0000000000000198","volume":"93","author":"A Paniccia","year":"2014","unstructured":"Paniccia A, Edil BH, Schulick RD, Byers JT, Meguid C, Gajdos C, McCarter MD. Neoadjuvant folfirinox application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study. Medicine. 2014;93:e198.","journal-title":"Medicine"},{"issue":"Suppl 3","key":"2821_CR20","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1245\/s10434-015-4783-x","volume":"22","author":"D Pietrasz","year":"2015","unstructured":"Pietrasz D, Marthey L, Wagner M, Blanc JF, Laurent C, Turrini O, Raoul JL, Terrebonne E, Hentic O, Trouilloud I, et al. Pathologic major response after folfirinox is prognostic for patients secondary resected for borderline or locally advanced pancreatic adenocarcinoma: an ageo-french, prospective, multicentric cohort. Ann Surg Oncol. 2015;22 Suppl 3:1196\u2013205.","journal-title":"Ann Surg Oncol"},{"key":"2821_CR21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.pan.2014.07.002","volume":"14","author":"S Valeri","year":"2014","unstructured":"Valeri S, Borzomati D, Nappo G, Perrone G, Santini D, Coppola R. Complete pathological response after folfirinox for locally advanced pancreatic cancer. the beginning of a new era? Case report and review of the literature. Pancreatology. 2014;14:425\u201330.","journal-title":"Pancreatology"},{"key":"2821_CR22","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.5858\/134.4.e8","volume":"134","author":"MK Washington","year":"2010","unstructured":"Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, et al. Protocol for the examination of specimens from patients with carcinoma of the distal extrahepatic bile ducts. Arch Pathol Lab Med. 2010;134:e8\u2013e13.","journal-title":"Arch Pathol Lab Med"},{"key":"2821_CR23","doi-asserted-by":"publisher","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","volume":"7","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.","journal-title":"PLoS Med"},{"key":"2821_CR24","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1002\/cncr.27636","volume":"118","author":"MH Katz","year":"2012","unstructured":"Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118:5749\u201356.","journal-title":"Cancer"},{"issue":"Suppl 7","key":"2821_CR25","doi-asserted-by":"publisher","first-page":"vii33","DOI":"10.1093\/annonc\/mds224","volume":"23","author":"T Seufferlein","year":"2012","unstructured":"Seufferlein T, Bachet JB, Van Cutsem E, Rougier P. Pancreatic adenocarcinoma: esmo-esdo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii33\u201340.","journal-title":"Ann Oncol"},{"key":"2821_CR26","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1093\/annonc\/mdt239","volume":"24","author":"V Heinemann","year":"2013","unstructured":"Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol. 2013;24:2484\u201392.","journal-title":"Ann Oncol"},{"key":"2821_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1245\/s10434-010-1456-7","volume":"18","author":"JB Stokes","year":"2011","unstructured":"Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, Rich TA, Adams RB, Bauer TW. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18:619\u201327.","journal-title":"Ann Surg Oncol"},{"key":"2821_CR28","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1245\/s10434-010-1284-9","volume":"17","author":"YS Chun","year":"2010","unstructured":"Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, Haluszka O, Tokar JL, Hall MJ, Denlinger CS, et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol. 2010;17:2832\u20138.","journal-title":"Ann Surg Oncol"},{"key":"2821_CR29","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/cncr.27736","volume":"119","author":"F Leone","year":"2013","unstructured":"Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, Regge D, Gabriele P, Capussotti L, Aglietta M. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer. 2013;119:277\u201384.","journal-title":"Cancer"},{"key":"2821_CR30","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1002\/cncr.28117","volume":"119","author":"EJ Kim","year":"2013","unstructured":"Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013;119:2692\u2013700.","journal-title":"Cancer"},{"key":"2821_CR31","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/SLA.0b013e31829b3ce4","volume":"258","author":"H Takahashi","year":"2013","unstructured":"Takahashi H, Ohigashi H, Gotoh K, Marubashi S, Yamada T, Murata M, Ioka T, Uehara H, Yano M, Ishikawa O. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg. 2013;258:1040\u201350.","journal-title":"Ann Surg"},{"key":"2821_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11605-011-1784-3","volume":"16","author":"CM Kang","year":"2012","unstructured":"Kang CM, Chung YE, Park JY, Sung JS, Hwang HK, Choi HJ, Kim H, Song SY, Lee WJ. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. J Gastrointest Surg. 2012;16:509\u201317.","journal-title":"J Gastrointest Surg"},{"key":"2821_CR33","first-page":"128","volume":"4","author":"MD Chuong","year":"2011","unstructured":"Chuong MD, Hayman TJ, Patel MR, Russell MS, Malafa MP, Hodul PJ, Springett GM, Choi J, Shridhar R, Hoffe SE. Comparison of 1-, 2-, and 3-dimensional tumor response assessment after neoadjuvant gtx-rt in borderline-resectable pancreatic cancer. Gastrointest Cancer Res. 2011;4:128\u201334.","journal-title":"Gastrointest Cancer Res"},{"key":"2821_CR34","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.2005.06.050","volume":"23","author":"T Conroy","year":"2005","unstructured":"Conroy T, Paillot B, Francois E, Bugat R, Jacob JH, Stein U, Nasca S, Metges JP, Rixe O, Michel P, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a groupe tumeurs digestives of the federation nationale des centres de lutte contre le cancer study. J Clin Oncol. 2005;23:1228\u201336.","journal-title":"J Clin Oncol"},{"key":"2821_CR35","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"2821_CR36","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1634\/theoncologist.2013-0273","volume":"19","author":"KK Christians","year":"2014","unstructured":"Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, et al. Neoadjuvant folfirinox for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014;19:266\u201374.","journal-title":"Oncologist"},{"key":"2821_CR37","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1245\/s10434-014-4225-1","volume":"22","author":"M Blazer","year":"2015","unstructured":"Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, et al. Neoadjuvant modified (m) folfirinox for locally advanced unresectable (lapc) and borderline resectable (brpc) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22:1153\u20139.","journal-title":"Ann Surg Oncol"},{"key":"2821_CR38","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.amjsurg.2011.03.008","volume":"203","author":"G Barugola","year":"2012","unstructured":"Barugola G, Partelli S, Crippa S, Capelli P, D'Onofrio M, Pederzoli P, Falconi M. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 2012;203:132\u20139.","journal-title":"Am J Surg"},{"key":"2821_CR39","doi-asserted-by":"publisher","first-page":"6433","DOI":"10.3748\/wjg.v13.i47.6433","volume":"13","author":"AZ Khan","year":"2007","unstructured":"Khan AZ, Pitsinis V, Mudan SS. Complete pathological response following down-staging chemoradiation in locally advanced pancreatic cancer: challenging the boundaries. World J Gastroenterol. 2007;13:6433\u20135.","journal-title":"World J Gastroenterol"},{"key":"2821_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1477-7819-11-37","volume":"11","author":"J Galindo","year":"2013","unstructured":"Galindo J, Gabrielli M, Guerra JF, Cassina JC, Garrido M, Jarufe N, Borghero Y, Madrid J, Zoroquiain P, Roa JC, et al. Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases. World J Surg Oncol. 2013;11:37.","journal-title":"World J Surg Oncol"},{"key":"2821_CR41","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S0360-3016(02)04157-3","volume":"55","author":"V Magnin","year":"2003","unstructured":"Magnin V, Moutardier V, Giovannini MH, Lelong B, Giovannini M, Viret F, Monges G, Bardou VJ, Alzieu C, Delpero JR. Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys. 2003;55:1300\u20134.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2821_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/00006676-200401000-00017","volume":"28","author":"V Magnin","year":"2004","unstructured":"Magnin V, Viret F, Moutardier V, Lelong B, Giovannini M, Monges G, Delpero JR. Complete pathologic responses to preoperative chemoradiation in two patients with adenocarcinoma of the pancreas. Pancreas. 2004;28:103\u20134.","journal-title":"Pancreas"},{"key":"2821_CR43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ijrobp.2004.04.004","volume":"60","author":"V Moutardier","year":"2004","unstructured":"Moutardier V, Magnin V, Turrini O, Viret F, Hennekinne-Mucci S, Goncalves A, Pesenti C, Guiramand J, Lelong B, Giovannini M, et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2004;60:437\u201343.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2821_CR44","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1245\/s10434-010-1019-y","volume":"17","author":"F Polistina","year":"2010","unstructured":"Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G. Unresectable locally advanced pancreatic cancer: A multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol. 2010;17:2092\u2013101.","journal-title":"Ann Surg Oncol"},{"key":"2821_CR45","first-page":"254","volume":"8","author":"MS Rajagopalan","year":"2013","unstructured":"Rajagopalan MS, Heron DE, Wegner RE, Zeh HJ, Bahary N, Krasinskas AM, Lembersky B, Brand R, Moser AJ, Quinn AE, et al. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Radiat. 2013;8:254.","journal-title":"Radiat"},{"key":"2821_CR46","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00280-009-0995-8","volume":"64","author":"M Reni","year":"2009","unstructured":"Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Zerbi A, Nicoletti R, Mazza E, Arcidiacono PG, Di Carlo V, et al. Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2009;64:1253\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2821_CR47","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s10434-001-0758-1","volume":"8","author":"RR White","year":"2001","unstructured":"White RR, Hurwitz HI, Morse MA, Lee C, Anscher MS, Paulson EK, Gottfried MR, Baillie J, Branch MS, Jowell PS, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol. 2001;8:758\u201365.","journal-title":"Ann Surg Oncol"},{"key":"2821_CR48","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1245\/ASO.2005.03.105","volume":"12","author":"RR White","year":"2005","unstructured":"White RR, Xie HB, Gottfried MR, Czito BG, Hurwitz HI, Morse MA, Blobe GC, Paulson EK, Baillie J, Branch MS, et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005;12:214\u201321.","journal-title":"Ann Surg Oncol"},{"key":"2821_CR49","first-page":"349","volume":"7","author":"R Wilkowski","year":"2006","unstructured":"Wilkowski R, Thoma M, Bruns C, Wagner A, Heinemann V. Chemoradiotherapy with gemcitabine and continuous 5-fu in patients with primary inoperable pancreatic cancer. Jop. 2006;7:349\u201360.","journal-title":"Jop"},{"key":"2821_CR50","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000439171","volume":"89","author":"E Ghorani","year":"2015","unstructured":"Ghorani E, Wong HH, Hewitt C, Calder J, Corrie P, Basu B. Safety and efficacy of modified folfirinox for advanced pancreatic adenocarcinoma: a uk single-centre experience. Oncology. 2015;89:281\u20137.","journal-title":"Oncology"},{"key":"2821_CR51","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1097\/MPA.0b013e31829e2006","volume":"42","author":"H Mahaseth","year":"2013","unstructured":"Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, Chen Z, Kooby DA, Maithel SK, Landry J, El-Rayes BF. Modified folfirinox regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42:1311\u20135.","journal-title":"Pancreas"},{"key":"2821_CR52","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.clinre.2014.08.011","volume":"39","author":"K Turner","year":"2015","unstructured":"Turner K, Levi Sandri GB, Boucher E, Henno S, Le Prise E, Meunier B, Boudjema K, Sulpice L. Complete radiological response of an initially locally advanced unresectable pancreatic cancer to chemoradiotherapy using folfirinox regimen: report of a case. Clin Res Hepatol Gastroenterol. 2015;39:e29\u201331.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2821_CR53","doi-asserted-by":"crossref","unstructured":"Cooper AB, Tzeng CW, Katz MH: Treatment of borderline resectable pancreatic cancer. CurrTreat Opt Oncol. 14:293\u2013310.","DOI":"10.1007\/s11864-013-0244-6"},{"key":"2821_CR54","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12032-012-0361-2","volume":"30","author":"KS Gunturu","year":"2013","unstructured":"Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM, Lacy J. Folfirinox for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Medical oncology (Northwood, London, England). 2013;30:361.","journal-title":"Medical oncology (Northwood, London, England)"},{"key":"2821_CR55","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/1471-2407-12-199","volume":"12","author":"PJ Hosein","year":"2012","unstructured":"Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, et al. A retrospective study of neoadjuvant folfirinox in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199.","journal-title":"BMC Cancer"},{"key":"2821_CR56","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.pan.2015.08.010","volume":"15","author":"M Khushman","year":"2015","unstructured":"Khushman M, Dempsey N, Maldonado JC, Loaiza-Bonilla A, Velez M, Carcas L, Dammrich D, Hurtado-Cordovi J, Parajuli R, Pollack T, et al. Full dose neoadjuvant folfirinox is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology. 2015;15:667\u201373.","journal-title":"Pancreatology"},{"key":"2821_CR57","unstructured":"Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, et al. Multi-institutional experience with folfirinox in pancreatic adenocarcinoma. Jop. 2013;13:497\u2013501."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2821-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-2821-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2821-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T01:56:07Z","timestamp":1657418167000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2821-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,10]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2821"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2821-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,10]]},"article-number":"786"}}